Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism: the randomized, placebo-controlled EPATH trial
Mineralocorticoid receptor (MR) antagonism may affect bone turnover via direct and indirect pathways involving parathyroid hormone, but randomized controlled trials are lacking. In a pre-specified analysis of the “Eplerenone in primary hyperparathyroidism” placebo-controlled, randomized trial (ISRCT...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Bone
Year: 2017, Volume: 105, Pages: 212-217 |
| ISSN: | 1873-2763 |
| DOI: | 10.1016/j.bone.2017.08.030 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.bone.2017.08.030 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S8756328217303253 
|
| Author Notes: | Nicolas Verheyen, Martin R. Grübler, Andreas Meinitzer, Christian Trummer, Verena Schwetz, Karin Amrein, Hans P. Dimai, Winfried März, Cristiana Catena, Dirk von Lewinski, Jakob Voelkl, Ioana Alesutan, Astrid Fahrleitner-Pammer, Helmut Brussee, Stefan Pilz, Andreas Tomaschitz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576275329 | ||
| 003 | DE-627 | ||
| 005 | 20220814161214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180612s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bone.2017.08.030 |2 doi | |
| 035 | |a (DE-627)1576275329 | ||
| 035 | |a (DE-576)506275329 | ||
| 035 | |a (DE-599)BSZ506275329 | ||
| 035 | |a (OCoLC)1341011400 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Verheyen, Nicolas |e VerfasserIn |0 (DE-588)1160970009 |0 (DE-627)1024362299 |0 (DE-576)506293181 |4 aut | |
| 245 | 1 | 0 | |a Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism |b the randomized, placebo-controlled EPATH trial |c Nicolas Verheyen, Martin R. Grübler, Andreas Meinitzer, Christian Trummer, Verena Schwetz, Karin Amrein, Hans P. Dimai, Winfried März, Cristiana Catena, Dirk von Lewinski, Jakob Voelkl, Ioana Alesutan, Astrid Fahrleitner-Pammer, Helmut Brussee, Stefan Pilz, Andreas Tomaschitz |
| 264 | 1 | |c 2017 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 14 September 2017 | ||
| 500 | |a Gesehen am 12.06.2018 | ||
| 520 | |a Mineralocorticoid receptor (MR) antagonism may affect bone turnover via direct and indirect pathways involving parathyroid hormone, but randomized controlled trials are lacking. In a pre-specified analysis of the “Eplerenone in primary hyperparathyroidism” placebo-controlled, randomized trial (ISRCTN 33941607), effects of eight weeks MR-blockade with eplerenone on bone turnover markers in 97 patients with primary hyperparathyroidism were tested. Mean age was 67.5±9.5years, and 76 (78.4%) were females. In analysis of covariance with adjustment for baseline values, eplerenone had no significant effect on isoform 5b of the tartrate-resistant acid phosphatase (TRAP), beta-crosslaps, N-terminal propeptide of procollagen type 1 (P1NP), osteocalcin and bone-specific alkaline phosphatase. There was no significant cross-sectional correlation between plasma aldosterone concentration or the aldosterone-to-renin ratio and markers of bone turnover in multivariate linear regression models at baseline. These data provide first evidence from a randomized and placebo-controlled trial that short-term MR antagonism may not affect bone turnover, at least in patients with primary hyperparathyroidism. | ||
| 650 | 4 | |a Bone turnover | |
| 650 | 4 | |a Eplerenone | |
| 650 | 4 | |a Mineralocorticoid receptor | |
| 650 | 4 | |a Primary hyperparathyroidism | |
| 650 | 4 | |a Randomized controlled trial | |
| 700 | 1 | |a März, Winfried |d 1958- |e VerfasserIn |0 (DE-588)1027603599 |0 (DE-627)729463605 |0 (DE-576)373454635 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone |d Amsterdam [u.a.] : Elsevier Science, 1985 |g 105(2017), Seite 212-217 |h Online-Ressource |w (DE-627)306320177 |w (DE-600)1496324-3 |w (DE-576)081952945 |x 1873-2763 |7 nnas |a Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism the randomized, placebo-controlled EPATH trial |
| 773 | 1 | 8 | |g volume:105 |g year:2017 |g pages:212-217 |g extent:6 |a Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism the randomized, placebo-controlled EPATH trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bone.2017.08.030 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S8756328217303253 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180612 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1027603599 |a März, Winfried |m 1027603599:März, Winfried |d 60000 |d 61400 |e 60000PM1027603599 |e 61400PM1027603599 |k 0/60000/ |k 1/60000/61400/ |p 8 | ||
| 999 | |a KXP-PPN1576275329 |e 3012511660 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Nicolas","family":"Verheyen","role":"aut","display":"Verheyen, Nicolas"},{"display":"März, Winfried","role":"aut","family":"März","given":"Winfried"}],"language":["eng"],"relHost":[{"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Bone","subtitle":"cell molecular biology, pathophysiology, treatment ; official journal of the International Bone and Mineral Society","title":"Bone"}],"note":["Gesehen am 22.01.2020","Ungezählte Beil.: Supplement"],"disp":"Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism the randomized, placebo-controlled EPATH trialBone","corporate":[{"display":"International Bone and Mineral Society","role":"isb"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["1496324-3"],"issn":["1873-2763"],"eki":["306320177"]},"part":{"volume":"105","year":"2017","extent":"6","pages":"212-217","text":"105(2017), Seite 212-217"},"pubHistory":["Nachgewiesen 6.1985 -"],"recId":"306320177","origin":[{"publisher":"Elsevier Science","dateIssuedDisp":"1985-","publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1985"}]}],"title":[{"title_sort":"Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism","title":"Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism","subtitle":"the randomized, placebo-controlled EPATH trial"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1016/j.bone.2017.08.030"],"eki":["1576275329"]},"physDesc":[{"extent":"6 S."}],"note":["Available online 14 September 2017","Gesehen am 12.06.2018"],"name":{"displayForm":["Nicolas Verheyen, Martin R. Grübler, Andreas Meinitzer, Christian Trummer, Verena Schwetz, Karin Amrein, Hans P. Dimai, Winfried März, Cristiana Catena, Dirk von Lewinski, Jakob Voelkl, Ioana Alesutan, Astrid Fahrleitner-Pammer, Helmut Brussee, Stefan Pilz, Andreas Tomaschitz"]},"recId":"1576275329","origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}]} | ||
| SRT | |a VERHEYENNIEFFECTOFEP2017 | ||